Thrombocytopenia News and Research

RSS

Thrombocytopenia is a condition in which there is a lower-than-normal number of platelets in the blood. It may result in easy bruising and excessive bleeding from wounds or bleeding in mucous membranes and other tissues.

PARP inhibitor combined with chemotherapy increases survival for newly diagnosed ovarian cancer patients

Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that initial treatment with the PARP inhibitor veliparib in combination with chemotherapy significantly increased progression-free survival for patients with newly diagnosed, metastatic high-grade serous ovarian cancer, according to the results of the VELIA trial.

28 Sep 2019

Shorter duration DAPT after PCI did not increase adverse events in high-bleeding risk patients, finds study

Data from the EVOLVE Short DAPT study found that shortened three-month dual antiplatelet therapy did not increase myocardial infarction or stent thrombosis in high bleeding risk patients treated with a contemporary drug-eluting stent.

27 Sep 2019

Researchers find synergistic connection between two deadly blood-clotting diseases

Two rare but potentially deadly blood-clotting diseases, namely thrombotic thrombocytopenic purpura, or TTP, and hemolytic uremic syndrome, or HUS, show similar pathologies -- a multitude of painful blockages in small blood vessels that cause varying degrees of organ injury throughout the body. However, the two disorders have distinct biological mechanisms.

8 Sep 2019

DNA vaccine for tick-borne disease ‘SFTS’ confers protection against lethal infection in ferrets

A KAIST research team reported the development of a DNA vaccine for Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV) which completely protects against lethal infection in ferrets.

29 Aug 2019

FDA approves new drug to treat patients with myelofibrosis

Today, the U.S. Food and Drug Administration approved Inrebic (fedratinib) capsules to treat adult patients with certain types of myelofibrosis.

18 Aug 2019

Researchers test new drug to treat patients with chylomicronemia syndrome

People with familial chylomicronemia syndrome are born with a genetic mutation that means they can't produce an enzyme called lipoprotein lipase.

9 Aug 2019

$FDA grants accelerated approval to new treatment for refractory multiple myeloma$

FDA grants accelerated approval to new treatment for refractory multiple myeloma

Today, the U.S. Food and Drug Administration granted accelerated approval to Xpovio (selinexor) tablets in combination with the corticosteroid dexamethasone for the treatment of adult patients with relapsed refractory multiple myeloma who have received at least four prior therapies and whose disease is resistant to several other forms of treatment, including at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.

3 Jul 2019

First chemoimmunotherapy regimen approved by FDA for patients with diffuse large B-cell lymphoma

Today, the U.S. Food and Drug Administration granted accelerated approval to Polivy (polatuzumab vedotin-piiq), in combination with the chemotherapy bendamustine and a rituximab product (a combination known as "BR"), to treat adult patients with diffuse large B-cell lymphoma (DLBCL) that has progressed or returned after at least two prior therapies.

10 Jun 2019

FDA extends indication of metastatic breast cancer treatment to include male patients

The U.S. Food and Drug Administration today is extending the indication of Ibrance (palbociclib) capsules in combination with specific endocrine therapies for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in male patients.

5 Apr 2019

New collaboration aims to prevent life-threatening adverse reactions to medications

The University of Arizona College of Medicine - Phoenix and Banner Health are collaborating to prevent life-threatening adverse reactions to medications.

27 Feb 2019

USC research could lay foundation for a vaccine against tick-borne virus

Two groundbreaking discoveries by USC researchers could lead to medications and a vaccine to treat or prevent a hemorrhagic fever transmitted by a new tick species before it spreads across the United States.

7 Jan 2019

Oral drug used to treat blood clots in cancer patients appears to be safe and effective

Mayo Clinic researchers have found that an oral drug, apixaban, used to treat blood clots in patients undergoing cancer therapy, is safe and effective.

4 Dec 2018

New clinical practice guidelines for managing venous thromboembolism released

Venous thromboembolism, a term referring to blood clots in the veins, is a highly prevalent and far-reaching public health problem that can cause disability and death.

28 Nov 2018

FDA approves new treatment for AML patients

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are 75 years of age or older or who have other chronic health conditions or diseases (comorbidities) that may preclude the use of intensive chemotherapy.

22 Nov 2018

Nexus announces availability of Arsenic Trioxide Injection in the US

Nexus Pharmaceuticals announced today the immediate availability in the United States for Arsenic Trioxide Injection. Nexus Pharmaceuticals' Arsenic Trioxide Injection is available as 10 mg per 10 mL vial for injection.

16 Nov 2018

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Genentech, a member of the Roche Group , announced today that the randomized Phase III CLL14 study, which evaluated fixed-duration Venclexta® in combination with Gazyva® in people with previously untreated chronic lymphocytic leukemia and co-existing medical conditions, met its primary endpoint and showed a statistically significant reduction in the risk of disease worsening or death compared to standard-of-care Gazyva plus chlorambucil.

1 Nov 2018

CNIO researchers link MASTL protein to origin of thrombocytopenia

The Cell Division and Cancer Group of the Spanish National Cancer Research Centre has discovered that MASTL, the protein whose function in the organism has not yet been sufficiently investigated, plays an important role in controlling the cytoskeleton, the structure that gives shape to the cells, and enables their mobility and capacity for grouping.

1 Nov 2018

Pfizer announces PALOMA-3 trial results in patients with HR+, HER2- metastatic breast cancer

Pfizer Inc. today announced detailed overall survival data from the PALOMA-3 trial, which evaluated IBRANCE (palbociclib) in combination with fulvestrant compared to placebo plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer whose disease progressed on or after prior endocrine therapy.

22 Oct 2018

Phase III trial reports positive results with HDAC inhibitor in advanced breast cancer patients

Epigenetic therapy with histone deacetylase inhibitors is worth pursuing in hormone receptor positive advanced breast cancer, suggests a phase III trial reported today at the ESMO 2018 Congress in Munich.